Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study.
Abdominal fat distribution is influenced by androgen levels in both men and women. The purpose of this study was to assess the effects on fat distribution of administering nandrolone decanoate (ND; an anabolic steroid with weak androgenic activity) or spironolactone (SP; an antiandrogen) in obese postmenopausal women. The design was a randomized, placebo-controlled, 9-month trial with simultaneous calorie restriction for weight loss. Women in all three groups lost comparable amounts of weight, but the ND-treated women gained lean mass relative to the other two groups (P < 0.0005) and lost more body fat than women in the SP group (P < 0.01). The resting metabolic rate also increased slightly in the ND group. ND treatment produced a gain in visceral fat, as determined by computed tomography scan, and a relatively greater loss of sc abdominal fat. SP-treated women lost significantly less sc fat than the other two groups. Serum cholesterol decreased in the placebo group, but increased slightly in the other two groups (significant for SP vs. placebo, P < 0.05). High density lipoprotein cholesterol decreased significantly in the ND-treated women. There were no significant changes in fasting glucose or insulin sensitivity. We conclude that administration of exogenous androgens modulates body composition in obese postmenopausal women and independently affects visceral and sc abdominal fat.
Lovejoy
J C
JC
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge 70803, USA. lovejoj@mhs.pbrc.edu
Bray
G A
GA
Bourgeois
M O
MO
Macchiavelli
R
R
Rood
J C
JC
Greeson
C
C
Partington
C
C
D000273:Adipose Tissue / Q000187:drug effects* / Q000473:pathology; D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000009:adverse effects / Q000494:pharmacology*; D001823:Body Composition / Q000187:drug effects*; D002318:Cardiovascular Diseases; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D009277:Nandrolone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D000077603:Nandrolone Decanoate; D009765:Obesity / Q000097:blood / Q000473:pathology*; D017698:Postmenopause; D012307:Risk Factors; D013148:Spironolactone / Q000009:adverse effects / Q000494:pharmacology
D000726:Androgen Antagonists; D000728:Androgens; D006728:Hormones; D013148:Spironolactone; D009277:Nandrolone; D000077603:Nandrolone Decanoate